logo

In 2019 is it safe to avoid prostate biopsy in men with Prostate Imaging Reporting and Data System (PI‐RADS) score 1 and 2 lesions reported on their multiparametric MRI (mpMRI)? In[...]
Multiparametric magnetic resonance imaging and follow-up to avoid prostate biopsy in 4259 men Abstract Objective To determine the proportion of men avoiding biopsy because of negat[...]
November’s Article of the Month was written by researchers primarily from New York City, USA: Guideline of Guidelines: Testosterone Replacement Therapy for Testosterone Defic[...]
The prostate cancer treatment armamentarium has expanded over the last decade to include taxane‐based chemotherapies (docetaxel, cabazitaxel), sipulecel‐T, radium‐233, and newer an[...]
The global prevalence of erectile dysfunction: a review Abstract Objective To evaluate the global prevalence of erectile dysfunction (ED); as well as its association with physiolog[...]
Nikita Bhatt is a Specialist Trainee in Urology in the East of England Deanery and a BURST Committee member @BURSTUrology NICE Guideline – Renal and ureteric stones: assessment and[...]
I would hope the answer to the question posed in the title is a universal ‘yes’; at least that is my experience with this complex and common disease. The concept that in 2019, we h[...]
Every week, the Editor-in-Chief selects an Article of the Week from the current issue of BJUI. The abstract is reproduced below and you can click on the button to read the full art[...]
In this issue of BJUI, Rezaee et al. [1] report on Google trends as a barometer of public interest in PSA screening and different types of prostate cancer treatment in the USA. Not[...]